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Abstract
We evaluated the association of blood monocyte and platelet activation markers with the risk of 
peripheral artery disease (PAD) in a multicenter study of atherosclerosis among African American 
and Caucasian patients. Flow cytometric analysis of blood cells was performed in 1791 
participants (209 cases with PAD and 1582 noncases) from the cross-sectional Atherosclerosis 
Risk in Communities Carotid Magnetic Resonance Imaging ([MRI] ARIC Carotid MRI) Study to 
assess platelet glycoproteins IIb and IIIa, P-selectin, CD40 ligand, platelet–leukocyte aggregates, 
monocyte lipopolysaccharide receptor, toll-like receptors (TLRs) 2 and 4, P-selectin glycoprotein 
ligand 1, cyclooxygenase 2, and myeloperoxidase. Multivariate regression analyses evaluated the 
association of cellular markers with the risk of PAD. After adjusting for age, race, and gender, 
platelet CD40L, and monocyte myeloperoxidase (mMPO) levels were significantly lower (P < .
001), and monocyte TLR-4 levels were higher (P = .03) in patients with PAD. With additional 
adjustments for conventional risk factors, mMPO remained inversely and independently 
associated with the risk of PAD (odds ratio [OR]: 0.35, P = .01).
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Introduction
Peripheral arterial disease (PAD) is caused by progressive atherosclerosis which occludes 
the arterial lumen with consequent ischemic tissue injury and severe clinical complications 
such as claudication and ulceration.1 Evidence from recent studies has established 
atherosclerosis as an inflammatory disorder.2,3 Atherosclerotic lesions are promoted by 
immune and inflammatory cells, notably lymphocytes and monocytes, that transmigrate into 
the arterial wall from circulating blood, as well as proinflammatory mediators and reactive 
oxygen species generated by blood and vascular cells.4 Although it is now established that 
leukocytes transmigrated from blood play an essential role in atherosclerosis, it remains 
uncertain whether blood cell function in the circulating blood is associated with 
atherosclerosis. Recent reports revealed a significant association of total white blood cell 
count with PAD and other atherosclerotic disorders.5,6 Limited data on these processes are 
available from population-based studies, mostly due to the complex measurement 
methodology. We postulated that blood platelet and monocyte activation and 
proinflammatory molecules are associated with the risk of PAD. To test this hypothesis, we 
examined the association between platelet and monocyte activation and proinflammatory 
markers, and cell aggregates, and the case status of PAD by flow cytometry using data from 




The ARIC study is a multicenter, cohort study of atherosclerosis among African American 
and Caucasian men and women from 4 US communities.7 The baseline examination was 
conducted from 1986 to 1989, and cohort members were reexamined triannually over 9 
years. The ARIC Carotid MRI study, which consisted of 2066 participants enrolled in 2005–
2006 from the ARIC cohort, was designed to further improve our understanding of cellular 
factors and their association with atheromatous plaques.8 Ankle and brachial systolic blood 
pressures were measured bilaterally using a standardized protocol. Pheripheral arterial 
disease was defined by a presence of reduced ankle–brachial blood pressure index (ABI) 
lower than 0.9. For this investigation, 1791 participants were available for analysis after 
excluding those with missing measures, resulting in 209 cases with PAD and 1582 noncases.
Flow Cytometry Measurements
We used whole blood flow cytometry (Coulter Epics XL, Beckman Coulter, Inc., Miami, 
FL) to measure platelet and monocyte antigen levels and platelet–leukocyte aggregates.9 
Blood samples were collected in Cyto-Chex BCT vacutainer tubes (Streck, Omaha, 
Nebraska) containing EDTA and a cell membrane stabilizer for blood cells.10 They were 
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shipped to the central laboratory by overnight courier, and samples were analyzed 
immediately after arrival. We measured the following markers: platelet CD41 (glycoprotein 
[GP]-IIb), CD61 (GP-IIIa), CD62P (P-selectin), and CD154 (CD40L); monocyte CD14 
(lipopolysaccharide [LPS] receptor), CD162 (P-selectin glycoprotein ligand 1 or PSGL-1), 
toll-like receptor 2 (TLR-2; CD242), TLR-4 (CD244), cyclooxygenase 2 (COX-2), 
myeloperoxidase (MPO), leukocyte CD45, and cell aggregates including platelet–monocyte, 
platelet–lymphocyte, and platelet–neutrophil aggregates (PMA, PLA, and PNA, 
respectively). Data are presented as proportion of cells expressing the antigen (%) and/or the 
relative level of antigen expression assessed by median fluorescent intensity (MFI). For cells 
expressing more than 90% of the antigen, only the MFI is reported.
Statistical Analysis
For all analyses, data were weighted by the inverse to reflect the population estimates using 
SAS callable SUDAAN software, version 9.0.1 (RTI, Research Triangle Park, North 
Carolina) to account for the complex survey design of the ARIC Carotid MRI Study. 
Bivariate relationships were explored by comparing simple or adjusted means or proportions 
between groups using the REGRESS procedure for continuous variables and the RLOGIST 
procedure for categorical variables (SUDAAN, Research Triangle Institute (RTI), Research 
Triangle Park, NC). Multivariate logistic regression models were used to assess independent 
associations of cellular markers with PAD status after adjustments for age, race, and gender 
(model 1), or additionally adjusted for diabetes, waist-to-hip ratio, total cholesterol, high-
density lipoprotein (HDL), C-reactive protein (CRP), smoking status, hypertension, and 
lipid-lowering medication use (model 2). Odds ratios (OR) for PAD were estimated by 
contrasting the highest versus the lowest tertile of cellular markers. For race-specific 
analyses, the entire sample was used to obtain unbiased standard error estimates in each of 
the race subgroups.
Results
Comparison of Platelet and Monocyte Markers Between Cases With PAD and Noncases
Of the 2066 ARIC cohort members who participated in the Carotid MRI Study, 275 were 
excluded from the present analysis because data were missing on PAD (n = 192) or cellular 
markers (n = 83). Of the 1791 remaining, 209 (11.7%) were classified as patients with PAD. 
Table 1 shows the demographic and cardiovascular risk factor characteristics by the case 
status of PAD. Consistent with previous reports, a number of conventional risk factors such 
as age, race, current smoking, body mass index (BMI), waist-to-hip ratio, blood pressure, 
and CRP levels were positively associated, while HDL cholesterol and alcohol intake were 
negatively associated with PAD. A higher proportion of cases with PAD versus noncases 
were hypertensive, diabetic, current smokers, or took lipid-lowering or antihypertensive 
medications. Plasma levels of total cholesterol and low-density lipoprotein (LDL) 
cholesterol were not significantly associated with PAD. The estimated glomerular filtration 
rate (eGFR) was lower in cases with PAD compared with noncases (P = .011).
When the mean MPO values were analyzed by level of renal disease as determined by eGFR 
(normal, mild, moderate, severe) using standard cut points there appeared to be clear linear 
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relationship between MPO and renal function (Table 2). The test of linear relationship 
across GFR level (decreasing MPO with increasing renal dysfunction) is P = .002.
A selective list of platelet and monocyte markers assessed by flow cytometry is shown in 
Table 3 by the case status PAD. Relative to noncases, participants with PAD had 
significantly higher MFI values for platelet CD61 and significantly lower values for platelet 
CD40L. Among the leukocyte markers, lymphocyte PSGL-1 values were higher in cases 
with PAD, while monocyte TLR-2 and MPO were lower in cases with PAD versus 
noncases. There were no significant differences in cell aggregates between cases with PAD 
and noncases. As shown in Table 4, MFI values for platelet CD40L and monocyte MPO 
(mMPO) remained significantly lower and percentages of monocyte TLR-4 higher in cases 
with PAD than noncases after adjustment for age, race, and gender. With additional 
adjustment for conventional risk factors, the association of platelet CD40L and PAD was 
attenuated and borderline nonsignificant (P = .06), while the mMPO associations remained 
significant. CD61 was no longer significantly associated with PAD in the adjusted models.
Odds Ratios of PAD by mMPO Tertiles
A major finding from analysis was the significant inverse association of mMPO with PAD 
case status. We further explored the associations by comparing the odds of PAD across 
tertiles of mMPO. Examining risk factors prevalence across the mMPO tertiles showed that 
age and prevalence of cigarette smoking declined as mMPO tertiles increased, while BMI 
and LDL-cholesterol were positively associated with mMPO tertiles (data not shown). 
Individuals in the middle and upper tertiles of mMPO were at lower risk of PAD than were 
individuals in the lowest tertile (Figure 1A). After adjustment for demographic variables and 
risk factors (model 2), the OR for PAD comparing the highest to the lowest tertile of mMPO 
was 0.45 (P = .002). Race-specific results given in Table 5 suggest that the negative 
association of mMPO tertile with PAD risk may be stronger in whites than blacks. After 
adjusting for age, race, gender, and other risk factors, the ORs for PAD comparing the 
highest to the lowest tertile of mMPO was 0.35 (P = .01), while the comparable ORs among 
blacks was 0.55 (P = .08). We further explored the associations between monocyte TLR-4 
and PAD case status by comparing the odds of PAD across tertiles of monocyte TLR-4 (%). 
After adjustment for age, race, and gender, higher TLR-4 tertile was associated with 
increased risk of PAD with an OR of 1.70 for the highest versus the lowest tertile (P = .03; 
Figure 1B, model 1). After further adjustment for risk factors, the association of TLR-4 with 
PAD was attenuated and no longer significant (OR = 1.52, P = .06) (Figure 1B, model 2). 
Race-specific analyses showed that the association between monocyte TLR-4 and risk of 
PAD was stronger in whites than blacks (OR for comparison of highest vs lowest tertile: 
1.98 vs 1.38 [model 1] or 1.69 vs 1.31 [model 2]).
Discussion
The aim of this study was to assess the relationship between various cell markers expressed 
by circulating blood platelets and monocytes and PAD in participants of the ARIC Carotid 
MRI study. A major finding was that monocyte enzyme MPO is inversely and 
independently associated with risk of PAD. Monocytic intracellular MPO levels were 
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significantly lower in PAD cases vs noncases, and the ORs for PAD of mMPO in the upper 
tertile were significantly reduced (~0.5) compared to those in the lower tertile. The inverse 
relationship between mMPO content and prevalence of PAD in our study may be explained 
by release and depletion of mMPO during monocyte activation.11 This possible explanation 
is supported by reports that plasma MPO levels are increased in patients with coronary heart 
disease and are associated with increased risk of major cardiac events.12,13 This notion is 
further strengthened by reports that humans with MPO deficiency or reduced MPO 
expression have reduced risk of cardiovascular diseases.14 Interestingly, Zhang et al12 found 
a positive association of leukocyte MPO content and coronary artery disease, while our 
study reports an inverse association of the intracellular mMPO and PAD. The reasons for 
this are not clear, but many differences between the 2 studies probably contributed to it. 
Namely, Zhang et al used multiple steps and procedures to isolate neutrophils from whole 
blood by centrifugation, which were then subjected to cell lyses, freezing, thawing, and then 
to an enzyme-linked immunosorbent assay (ELISA) which uses polyclonal antibody to 
MPO. The MPO was expressed per milligram of total cell proteins. In our study, monocytes 
were analyzed directly in whole blood, without centrifugation steps which are known to 
contribute to loss of some cells, and mMPO was expressed as the median MPO content per 
single cell. Monocyte MPO was quantified by a direct immunostaining with a specific 
monoclonal antibody raised against purified human MPO and directly conjugated to FITC; it 
has been optimized to recognize the human intracellular MPO in whole blood samples. It is 
likely that the 2 antibodies (a polyclonal used in ELISA and monoclonal in our flow 
cytometry) recognize different epitopes at the MPO molecule.
Macrophage MPO has been detected in human atherosclerotic lesions and considered to play 
an important role in tissue inflammation and injury.15 It was recently reported that MPO-
positive neutrophils accumulate in mice with atherosclerotic lesions.16 However, MPO data 
from murine experiments should be interpreted with caution as differences between human 
and murine MPO expression in leukocytes exist.17 Myeloperoxidase is a member of the 
heme peroxidase superfamily. It constitutes about 5% of human neutrophil protein and 
catalyzes the conversion of hydrogen peroxide (H2O2) to hypochlorous acid (HOCl). Upon 
activation, neutrophils secrete large quantities of MPO which produces HOCl that reacts 
with plasma constituents such as LDL, HDL, and endothelial cells to promote 
atherosclerosis and other forms of vascular diseases. The MPO content in circulating 
monocytes is lower than that in neutrophils and has been reported to constitute about 1% of 
monocyte proteins.18 Our results suggest that MPO in human monocytes is about 10% of 
that in neutrophils (data not shown). Prior results on the association of neutrophil MPO 
content with PAD are controversial. Brevetti et al19 reported a reduced neutrophil MPO 
content in patients with coronary artery disease having PAD compared to those without 
PAD. Monaco et al20 evaluated inflammatory and prothrombotic markers in hospitalized 
patients with unstable angina (UA) and PAD and found neutrophil activation, as assessed by 
its intracellular content of myeloperoxidase (using a different methodology), was only 
observed in UA but not in patients with PAD, suggesting that atheroma burden is less 
related to neutrophil MPO content than systemic inflammation in UA. In the study by 
Buffon et al11 intra-leukocyte MPO staining using a hematologic analyzer was assessed in 
participants with stable and unstable coronary artery disease sampled at both the coronary 
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artery and the cardiac vein, allowing for evaluation of a “transcoronary inflammation 
gradient” across inflamed vascular bed in unstable. These studies supported widespread 
activation of neutrophils across the coronary vascular bed in patients with UA, indicating 
that patients with more “vulnerable plaque” show greater reduction in leukocyte MPO 
content.
To our best knowledge, the association of mMPO content with PAD has not been previously 
reported. The flow cytometry assay allows for measuring intracellular MPO content in 
individual cells independent of the total white blood cell count which is a major factor 
affecting measurements of serum MPO levels. Our data thus provide novel information 
concerning the role of mMPO in PAD. Whether these markers relate to incident adverse 
events is an important question. The ARIC will eventually try to address this question but 
currently the sample size, and therefore the number of incident adverse events is too low, to 
address it yet.
It is well recognized that monocytes play a key role in atherogenesis. They transmigrate the 
endothelium to enter the vascular wall where they mediate inflammation and generate foam 
cells. The National Health and Nutrition Examination Survey study reported that monocytes 
are the only leukocyte subtype significantly associated with PAD.21 A previous report 
suggested the proinflammatory potential of monocytes in an in vitro model was higher in 
patients with PAD than in controls.22 Our data provide a more direct evidence for an 
association of circulating blood monocyte activation with PAD risk.
Blood monocyte activation may be triggered by diverse agents such as LPS, other microbial 
products, as well as CD40 ligand and P-selectin. Stimulating agents activate monocytes by 
interacting with specific receptors on the monocyte surface. We analyzed the association 
with PAD of monocyte TLR-4 and CD14, receptors for LPS; TLR-2, receptor for other 
bacterial products; and PSGL-1, receptors for P-selectin. We also included platelet P-
selectin, ligand of PSGL-1 and platelet CD40L, and ligand ofCD40 in this association study. 
After adjustment for age, gender, and race, monocyte TLR-4 was significantly associated 
with PAD risk. However, the association became insignificant after additional adjustment 
for cardiovascular risk factors, suggesting that association is explained by confounding 
factors.
Previous studies have demonstrated that TLR-4 expression is upregulated in human 
atherosclerotic plaques and in animal models.23,24 Furthermore, TLR-4 together with CD14 
polymorphisms synergistically influences atherosclerosis in patients with PAD.25 Thus, 
circulating monocyte TLR-4 is an important player not only in atherosclerotic progression 
but also in atherogenesis.
Platelet activation results in secretion of CD40L and P-selectin. CD40L interacts with CD40 
on monocytes and transmits signals to activate monocytes and has been shown to play an 
important role in atherosclerosis.26,27 P-selectin mediates leukocyte transmigration into the 
vessel wall and interacts with PSGL-1 to activate monocyte. Furthermore, P-selectin is 
involved in platelet aggregate formation. Analysis by flow cytometry in this study showed 
that cases with PAD had significantly lower levels of CD40L than noncases although after 
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adjustments for traditional risk factors it had borderline significance (P = .06). Platelet 
CD40L correlated with P-selectin, and both activation markers showed an inverse 
correlation with the percentage of single, nonactivated platelets (r = −.30 and −.27, 
respectively), indicating increased platelet activation. On the other hand, it is possible that 
lower platelet CD40L expression in PAD may be attributed to its engagement to platelet–
leukocyte aggregate formation (through CD40-CD40L interactions).
In our study, platelet–leukocyte complexes were not associated with PAD. Several studies 
reported platelet hyper-reactivity and elevation, while others reported lower platelet P-
selectin in patients with PAD compared to controls.28–30 The differences may be explained 
by differences in patient selection and study design.
Interestingly, when data were analyzed by ethnic origin, and after adjusting for traditional 
risk factors, the magnitude of the association between mMPO and PAD risk was stronger in 
whites than blacks. This observation deserves further investigation because PAD is less 
prevalent in Caucasians than African Americans.31 It also may be due to the relatively small 
sample size for African Americans.
This study has potential limitations. The cross-sectional design allows us to estimate the 
associations reported herein but not to establish cause and effect relations. Thus, based on 
biologic and mechanistic plausibility, our results suggest a pathogenic role of selected 
cellular markers but do not establish their antecedent role. Similarly, since genetic and 
environmental variations modulate MPO expression, we cannot exclude the effect of either 
source of variability, nor apportion the role of either, in the observed mMPO levels. Genetic 
studies are underway in the ARIC Carotid MRI participants. A drawback of our study is that 
we did not collect data to distinguish whether participants with low ABI were symptomatic 
or not. Since they were outpatients who could come to an examination center and were 
detected as having PAD by ABI screening, we presume most were asymptomatic. Monaco 
and others19,20 have suggested that unstable vascular disease results in the depletion of 
leukocyte MPO content. Therefore, our pooling for this study of symptomatic (presumably 
unstable) and nonsymptomatic patients with low ABI may have diluted the observed 
association of mMPO with PAD. A final limitation is that we only had a single measurement 
of cellular markers and although most of the measurements have good reliability,8 
measurement error would tend to weaken observed association.
In conclusion, the results of this study demonstrate that monocyte activation is associated 
with PAD and suggest that they play roles in the pathogenesis of atherosclerosis as indexed 
by PAD. Our results also provide strong support for a role of MPO as a PAD risk factor, 
particularly in Caucasians.
Acknowledgments
We thank the staff and participants of the ARIC study for their important contributions. We thank Dr. Diane 
Catellier for providing additional statistical analysis. In addition, thanks are extended to Dr R Michelle Sauer for 
editorial support.
Funding
Matijevic (Aleksic) et al. Page 7













The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: 
The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, 
Lung, and Blood Institute contracts N01-HC- 55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC- 
55020, N01-HC-55021, and N01-HC-55022 with the ARIC carotid MRI examination funded by U01HL075572-01.
References
1. Ouriel K. Peripheral arterial disease. Lancet. 2001; 358(9289):1257–1264. [PubMed: 11675083] 
2. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999; 340(2):115–126. 
[PubMed: 9887164] 
3. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420(6917):868–874. [PubMed: 12490960] 
4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 
352(16):1685–1695. [PubMed: 15843671] 
5. Elkind MS, Cheng J, Boden-Albala B, Paik MC, Sacco RL. Elevated white blood cell count and 
carotid plaque thickness: the northern Manhattan stroke study. Stroke. 2001; 32(4):842–849. 
[PubMed: 11283380] 
6. Lee CD, Folsom AR, Nieto FJ, Chambless LE, Shahar E, Wolfe DA. White blood cell count and 
incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease 
in African-American and White men and women: atherosclerosis risk in communities study. Am J 
Epidemiol. 2001; 154(8):758–764. [PubMed: 11590089] 
7. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and 
objectives. Am J Epidemiol. 1989; 129(4):687–702. [PubMed: 2646917] 
8. Folsom AR, Aleksic N, Sanhueza A, Boerwinkle E. Risk factor correlates of platelet and leukocyte 
markers assessed by flow cytometry in a population-based sample. Atherosclerosis. 2008; 205(1):
272–278. [PubMed: 19124123] 
9. Catellier DJ, Aleksic N, Folsom AR, Boerwinkle E. Atherosclerosis Risk in Communities (ARIC) 
Carotid MRI Flow Cytometry study of monocyte and platelet markers: intraindividual variability 
and reliability. Clin Chem. 2008; 54(8):1363–1371. [PubMed: 18515256] 
10. Warrino DE, DeGennaro LJ, Hanson M, Swindells S, Pirruccello SJ, Ryan WL. Stabilization of 
white blood cells and immunologic markers for extended analysis using flow cytometry. J 
Immunol Methods. 2005; 305(2):107–119. [PubMed: 16214501] 
11. Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A. Widespread coronary 
inflammation in unstable angina. N Engl J Med. 2002; 347(1):5–12. [PubMed: 12097534] 
12. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of 
coronary artery disease. JAMA. 2001; 286(17):2136–2142. [PubMed: 11694155] 
13. Baldus S, Heeschen C, Meinertz T, et al. CAPTURE Investigators. Myeloperoxidase serum levels 
predict risk in patients with acute coronary syndromes. Circulation. 2003; 108(12):1440–1445. 
[PubMed: 12952835] 
14. Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A. Consequences of total 
and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol. 2000; 104(1):10–15. 
[PubMed: 11111115] 
15. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage 
myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human 
atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001; 158(3):879–
891. [PubMed: 11238037] 
16. van Leeuwen M, Gijbels MJ, Duijvestijn A, et al. Accumulation of myeloperoxidase-positive 
neutrophils in atherosclerotic lesions in LDLR−/− mice. Arterioscler Thromb Vasc Biol. 2008; 
28(1):84–89. [PubMed: 17991873] 
17. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc 
Biol. 2005; 25(6):1102–1111. [PubMed: 15790935] 
18. Bos A, Wever R, Roos D. Characterization and quantification of the peroxidase in human 
monocytes. Biochim Biophys Acta. 1978; 525(1):37–44. [PubMed: 28769] 
Matijevic (Aleksic) et al. Page 8













19. Brevetti G, Schiano V, Laurenzano E, et al. Myeloperoxidase, but not C-reactive protein, predicts 
cardiovascular risk in peripheral arterial disease. Eur Heart J. 2008; 29(2):224–230. [PubMed: 
18156137] 
20. Monaco C, Rossi E, Milazzo D, et al. Persistent systemic inflammation in unstable angina is 
largely unrelated to the atherothrombotic burden. J Am Coll Cardiol. 2005; 45(2):238–243. 
[PubMed: 15653021] 
21. Nasir K, Guallar E, Navas-Acien A, Criqui MH, Lima JA. Relationship of monocyte count and 
peripheral arterial disease: results from the National Health and Nutrition Examination Survey 
1999–2002. Arterioscler Thromb Vasc Biol. 2005; 25(9):1966–1971. [PubMed: 15976323] 
22. Luu NT, Madden J, Calder PC, et al. Comparison of the pro-inflammatory potential of monocytes 
from healthy adults and those with peripheral arterial disease using an in vitro culture model. 
Atherosclerosis. 2007; 193(2):259–268. [PubMed: 16982061] 
23. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human 
atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002; 105(10):1158–
1161. [PubMed: 11889007] 
24. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. 
J Clin Invest. 2005; 115(11):3149–3156. [PubMed: 16211093] 
25. Vainas T, Stassen FR, Bruggeman CA, et al. Synergistic effect of Toll-like receptor 4 and CD14 
polymorphisms on the total atherosclerosis burden in patients with peripheral arterial disease. J 
Vasc Surg. 2006; 44(2):326–332. [PubMed: 16890863] 
26. Young RS, Naseem KM, Pasupathy S, Ahilathirunayagam S, Chaparala RP, Homer-Vanniasinkam 
S. Platelet membrane CD154 and sCD154 in progressive peripheral arterial disease: a pilot study. 
Atherosclerosis. 2007; 190(2):452–458. [PubMed: 16777115] 
27. Blann AD, Tan KT, Tayebjee MH, Davagnanam I, Moss M, Lip GY. Soluble CD40L in peripheral 
artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. 
Thromb Haemost. 2005; 93(3):578–583. [PubMed: 15735813] 
28. Rajagopalan S, Mckay I, Ford I, Bachoo P, Greaves M, Brittenden J. Platelet activation increases 
with the severity of peripheral arterial disease: implications for clinical management. J Vasc Surg. 
2007; 46(3):485–490. [PubMed: 17826235] 
29. Robless PA, Okonko D, Lintott P, Mansfield AO, Mikhailidis DP, Stansby GP. Increased platelet 
aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2003; 25(1):
16–22. [PubMed: 12525806] 
30. McBane RD 2nd, Karnicki K, Miller RS, Owen WG. The impact of peripheral arterial disease on 
circulating platelets. Thromb Res. 2004; 113(2):137. [PubMed: 15115669] 
31. Kullo IJ, Bailey KR, Kardia SL, Mosley TH Jr, Boerwinkle E, Turner ST. Ethnic differences in 
peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy 
(GENOA) study. Vasc Med. 2003; 8(4):237–242. [PubMed: 15125483] 
Matijevic (Aleksic) et al. Page 9














A, Adjusted odds ratios (ORs) of PAD by tertile of monocyte myeloperoxidase (mMPO, 
MFI). Tertile 1 (white bars): 6.1–79.9; tertile 2 (shaded bars): 79.9–100; tertile 3 (black 
bars): 100–209.1. B, Adjusted odds ratios (ORs) of PAD by tertile of monocyte TLR-4 (%). 
Tertile 1 (white bars): 49.3–63.4; tertile 2 (shaded bars): 63.4–66.7; tertile 3 (black bars): 
66.7–95.0. Model 1: Adjusted for age, race, and gender. Model 2: Also adjusted for diabetes, 
waist-to-hip ratio, TC, HDL, CRP, smoking status, hypertension and lipid-lowering 
medication use. PAD indicates peripheral arterial disease; MFI, median fluorescent 
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intensity; TLR, toll-like receptor; TC, total cholesterol; HDL, high-density lipoprotein; CRP, 
C-reactive protein.
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Table 1
Characteristics of the ARIC Carotid MRI Study Sample by the Case Status of PADa
Characteristic PAD Cases (n = 209) PAD Noncases (n = 1582) P Value
Age, years 73.0 (5.8) 69.8 (5.4) <.001
Race (black), % 48 19 <.001
Sex (female), % 59 55 .43
Body mass index (BMI), kg/m2 30.4 (5.5) 28.9 (5.3) .01
Waist-to-hip ratio 0.96 (0.1) 0.94 (0.1) <.001
Total cholesterol, mg/dL 191 (42) 195 (41) .31
Lipid lowering medication use, % 55 39 .001
LDL cholesterol, mg/dL 113 (38) 114 (36) .90
HDL cholesterol, mg/dL 47 (12) 50 (15) .01
Log CRP, mg/L 1.00 (1.1) 0.73 (1.0) .01
Ethanol intake, g/week 25 (64) 38 (88) .03
Systolic blood pressure, mm Hg 130 (20) 125 (18) .01
Hypertensive, % 85 62 <.001
Antihypertensive use, % 60 42 <.001
Diabetes, % 41 22 <.001
Current smoker, % 19 7 <.001
Former smoker, % 48 41 .11
eGFR, mL/min per 1.73 m2 79 (27) 81 (23) .01
Abbreviations: ARIC, Atherosclerosis Risk in Communities; PAD, peripheral arterial disease; eGFR, estimated glomerular filtration rate; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; CRP, C-reactive protein.
a
Presented are demographic and cardiovascular risk factor characteristics by the case status of PAD and the statistical significance of their 
association with PAD. Values are presented as mean (SD) unless otherwise indicated.
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Table 2
Myeloperoxidase Values, Mean (SD) by Level of Renal Disease Determined by eGFRa
eGFR N MPO (MFI)
Normal: ≥90 507 94.6 (26.8)
Mild: 60–90 946 92.3 (24.3)
Moderate: 30–60 283 87.3 (23.6)
Severe: <30 12 84.8 (19.5)
Abbreviations: eGFR = estimated glomerular filtration rate, ml/min per 1.73 m2; MPO, myeloperoxidase; MFI, median fluorescent intensity.
a
The test of linear relationship across GFR level (decreasing MPO with increasing renal dysfunction) is P = .002.













Matijevic (Aleksic) et al. Page 14
Table 3
Unadjusted Means (SD) of Flow Cytometry Parameters by the Case Status of PADa,b
Flow Cytometry Parameter PAD Cases (n = 209) PAD Noncases (n = 1582) P Value
Platelets
  CD41, MFI 80.5 (13.9) 78.9 (12.3) .22
  CD61, MFI 65.1 (18.4) 60.9 (17.8) .01
  CD62P, % 28.5 (15.3) 28.5 (14.0) .98
  CD62P, MFI 23.0 (8.0) 21.8 (5.6) .58
  CD40L, % 2.9 (1.8) 2.9 (2.5) .99
  CD40L, MFI 12.2 (1.1) 12.5 (1.8) <.001
Leukocytesc
  CD14, MFI 112.1 (22.4) 111.8 (20.8) .86
  TLR-2, % 60.6 (12.2) 62.6 (11.7) .07
  TLR-2, MFI 13.8 (1.2) 14.0 (1.4) .04
  TLR-4, % 65.5 (4.0) 65.0 (4.1) .17
  TLR-4, MFI 16.5 (1.0) 16.4 (1.0) .43
  PSGL-1, MFI 114.6 (16.2) 111.9 (15.2) .07
  lPSGL-1, MFI 56.8 (11.3) 53.2 (10.6) <.001
  COX-2, % 98.1 (2.5) 98.1 (3.6) .97
  COX-2, MFI 17.0 (2.9) 17.4 (2.8) .13
  CD45, MFI 75.4 (12.4) 75.0 (9.8) .76
  lCD45, MFI 195.7 (24.7) 198.0 (26.1) .37
  MPO, MFI 85.8 (27.2) 92.8 (24.8) <.01
Cell aggregates
  PMA, % 17.6 (4.2) 17.6 (4.3) .99
  PLA, % 17.0 (4.1) 16.9 (4.2) .73
  PNA, % 16.9 (4.2) 16.9 (4.2) .90
Abbreviations: ARIC, Atherosclerosis Risk in Communities; MRI, magnetic resonance imaging; PAD, peripheral arterial disease; eGFR, estimated 
glomerular filtration rate; MFI, median fluorescent intensity; TLR, toll-like receptor; PSGL, P-selectin glycoprotein ligand; COX, cyclooxygenase; 
MPO, myeloperoxidase; PMA, platelet–monocyte aggregate; PLA, platelet–lymphocyte aggregate; PNA, platelet–neutrophil aggregate.
a
The ARIC Carotid MRI Study.
b
Presented are measures of platelet and monocyte markers assayed by flow cytometry in cases with PAD and noncases and the statistical 
significance of their association with the case status of PAD.
c
Results are for monocytes unless labeled differently (l = lymphocytes)
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Table 4
Adjusted Means (SE) of Selecteda Flow Cytometry Parameters by the Case Status of PADb,c
Flow Cytometry Parameter PAD Cases (n = 209) PAD Noncases (n = 1582) P Value
Platelets
  CD40L, MFI Model 1d 12.2 (0.09) 12.5 (0.06) .003
Model 2e 12.3 (0.10) 12.5 (0.06) .06
Monocytes
  TLR-4, % Model 1 65.8 (0.38) 65.0 (0.13) .03
Model 2 65.7 (0.39) 65.0 (0.13) .08
  MPO, MFI Model 1 82.6 (2.31) 93.1 (0.74) <.001
Model 2 83.8 (2.37) 93.0 (0.75) <.001
Abbreviations: ARIC, Atherosclerosis Risk in Communities; MRI, magnetic resonance imaging; PAD, peripheral arterial disease; MFI, median 
fluorescent intensity; TLR, toll-like receptor; MPO, myeloperoxidase; TC, total cholesterol; HDL, high-density lipoprotein; CRP, C-reactive 
protein.
a
Parameters with significant (P < .05) difference in age, race, and gender-adjusted means.
b
The ARIC Carotid MRI Study.
c
Presented are flow cytometry measures of platelet and monocyte markers in PAD cases and non-cases analyzed by 2 statistical models:
d
Model 1: adjusted for age, race, and gender.
e
Model 2: also adjusted for diabetes, waist-to-hip ratio, TC, HDL, CRP, smoking status, hypertension, and lipid-lowering medication use.
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